Department of Oncology, Queen’s University, Kingston, Ontario, Canada.
JAMA. 2011 Jun 8;305(22):2335-42. doi: 10.1001/jama.2011.749.
Adjuvant chemotherapy (AC) improves survival among patients with resected colorectal cancer. However, the optimal timing from surgery to initiation of AC is unknown.
To determine the relationship between time to AC and survival outcomes via a systematic review and meta-analysis. data sources: MEDLINE (1975 through January 2011), EMBASE, the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials were searched to identify studies that described the relationship between time to AC and survival.
Studies were only included if the relevant prognostic factors were adequately described and either comparative groups were balanced or results adjusted for these prognostic factors.
Hazard ratios (HRs) for overall survival and disease-free survival from each study were converted to a regression coefficient (β) and standard error corresponding to a continuous representation per 4 weeks of time to AC. The adjusted β from individual studies were combined using a fixed-effects model. Inverse variance (1/SE(2)) was used to weight individual studies. Publication bias was investigated using the trim and fill approach.
We identified 10 eligible studies involving 15,410 patients (7 published articles, 3 abstracts). Nine of the studies were cohort or population based and 1 was a secondary analysis from a randomized trial of chemotherapy. Six studies reported time to AC as a binary variable and 4 as 3 or more categories. Meta-analysis demonstrated that a 4-week increase in time to AC was associated with a significant decrease in both overall survival (HR, 1.14; 95% confidence interval [CI], 1.10-1.17) and disease-free survival (HR, 1.14; 95% CI, 1.10-1.18). There was no significant heterogeneity among included studies. Results remained significant after adjustment for potential publication bias and when the analysis was repeated to exclude studies of largest weight.
In a meta-analysis of the available literature on time to AC, longer time to AC was associated with worse survival among patients with resected colorectal cancer.
辅助化疗(AC)可提高结直肠癌患者的生存率。然而,从手术到开始辅助化疗的最佳时间尚不清楚。
通过系统评价和荟萃分析确定 AC 时间与生存结果之间的关系。
检索 MEDLINE(1975 年至 2011 年 1 月)、EMBASE、Cochrane 系统评价数据库和 Cochrane 对照试验中心注册库,以确定描述 AC 时间与生存关系的研究。
只有当相关预后因素得到充分描述并且比较组平衡或结果针对这些预后因素进行调整时,研究才被包括在内。
每项研究的总生存和无病生存的风险比(HR)转换为回归系数(β)和对应于每 4 周 AC 时间的连续表示的标准误差。使用固定效应模型合并来自个别研究的调整后β。使用逆方差(1/SE(2))为个别研究加权。使用修剪和填充方法调查发表偏倚。
我们确定了 10 项符合条件的研究,涉及 15410 名患者(7 篇已发表文章,3 篇摘要)。9 项研究为队列或人群研究,1 项为化疗随机试验的二次分析。6 项研究报告 AC 时间为二分类变量,4 项研究为 3 个或更多类别。荟萃分析表明,AC 时间每增加 4 周,总生存(HR,1.14;95%置信区间 [CI],1.10-1.17)和无病生存(HR,1.14;95%CI,1.10-1.18)均显著降低。纳入研究之间无显著异质性。在调整潜在发表偏倚后,结果仍然显著,并且当分析重复以排除权重最大的研究时,结果仍然显著。
在对可获得的关于 AC 时间的文献进行荟萃分析后,AC 时间延长与接受结直肠癌切除术的患者的生存状况较差相关。